|
Nov 28
|
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
|
|
Nov 28
|
Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study
|
|
Nov 27
|
Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study
|
|
Nov 27
|
Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan
|
|
Nov 8
|
Compared to Estimates, Ligand (LGND) Q3 Earnings: A Look at Key Metrics
|
|
Nov 8
|
Ligand Pharmaceuticals Inc (LGND) Reports Q3 2023 Financial Results with Increased Revenue Guidance
|
|
Nov 8
|
Ligand Reports Third Quarter 2023 Financial Results
|
|
Nov 7
|
bluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Sales
|
|
Nov 6
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Nov 6
|
Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial
|
|
Nov 3
|
Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated
|
|
Nov 3
|
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
|
|
Nov 3
|
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
|
|
Nov 2
|
Zoetis' (ZTS) Q3 Earnings Beat, Revenues Miss by a Whisker
|
|
Oct 26
|
Ligand Pharmaceuticals (LGND) Advances While Market Declines: Some Information for Investors
|
|
Oct 26
|
LGND vs. ILMN: Which Stock Is the Better Value Option?
|
|
Oct 25
|
Ligand To Report Third Quarter 2023 Financial Results On November 8
|
|
Oct 25
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
|
Oct 24
|
Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-Term
|
|
Aug 9
|
Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings
|